Sichenzia Ross Ference Kesner LLP Represents Laidlaw & Company (UK) Ltd. in $5.2 Million Public Offering
Press Release – New York, NY – May 8, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented Laidlaw & Company (UK) Ltd. as sole book-running manager in the underwritten public offering of equity securities of Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). In connection with the offering, Onconova received approximately $5.2 million in gross proceeds from common stock sold at a price to the public of $2.10 per share.
The Sichenzia Ross Ference Kesner LLP team was led by Partners Harvey Kesner and Avital Perlman and associate Evan Berger.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Congratulates AYTU Biosciences, Inc., on NASDAQ Uplisting - October 19, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar and Fordham Financial Management in $6.75 Million Registered Direct Offering of Common Stock of Ampio Pharmaceuticals, Inc. - October 18, 2017
- Sichenzia Ross Ference Kesner LLP Advises US Gold Corp. on $2.5 Million Public Offering - October 13, 2017